创胜集团-B(06628.HK) 公布,于2025年美国癌症研究协会年会(AACR)上公布,基于新型人源化FGFR2b抗体的ADC(TST105)的最新临床前研究结果。该ADC采用糖基转移酶介导的定点偶联技术,搭载新型拓扑异构酶I抑制剂作为有效载荷,在临床前胃癌和结直肠癌模型中,相比以MMAE为载荷的ADC,展现出显著增强的抗肿瘤活性。据体外实验数据显示,TST105具有显著的内化作用、特异性杀伤...
Source Link创胜集团-B(06628.HK) 公布,于2025年美国癌症研究协会年会(AACR)上公布,基于新型人源化FGFR2b抗体的ADC(TST105)的最新临床前研究结果。该ADC采用糖基转移酶介导的定点偶联技术,搭载新型拓扑异构酶I抑制剂作为有效载荷,在临床前胃癌和结直肠癌模型中,相比以MMAE为载荷的ADC,展现出显著增强的抗肿瘤活性。据体外实验数据显示,TST105具有显著的内化作用、特异性杀伤...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.